Drug intelligence / Profile preview

lats2 small interfering RNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intramuscular, Intranasal, Intratumoral, Intraperitoneal, Subcutaneous, Intradermal
01

Overview

LATS2 small interfering RNA (siRNA) is a double-stranded RNA molecule designed to specifically silence the expression of the Large Tumor Suppressor Kinase 2 (LATS2) gene through the RNA interference (RNAi) pathway. LATS2 is a core component of the Hippo signaling pathway, which plays a critical role in regulating cell proliferation, apoptosis, and organ size. In oncology research, LATS2 is often identified as a tumor suppressor that is downregulated in various cancers, including colorectal cancer, often through the action of microRNAs such as miR-135b. By utilizing LATS2 siRNA in laboratory settings, researchers can mimic the loss of LATS2 function to investigate its contribution to chemoresistance and anti-apoptotic phenotypes. Experimental evidence in colorectal cancer models suggests that the miR-135b/LATS2 axis is a significant regulator of doxorubicin-induced apoptosis, making LATS2 a key target for understanding cancer progression and potential therapeutic intervention.

Other names
LATS2 siRNALATS-2 siRNALATS 2 siRNAsi-LATS2si-LATS-2si-LATS 2small interfering RNA targeting LATS2
02

Targets

LATS2 (Large tumor suppressor kinase 2)

Beyond the preview

Go deeper on lats2 small interfering RNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lats2 small interfering RNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call